Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.24%
1,103.05
+2.67
+0.24%
—1,100.381,096.191,112.971,094.08——
SIXC
Communications
SIXC
Communications
SIXC
+0.19%
622.42
+1.21
+0.19%
—621.21621.21624.47618.56——
SIXE
Energy
SIXE
Energy
SIXE
-2.87%
1,157.44
-34.22
-2.87%
—1,191.661,158.281,160.761,124.17——
SIXI
Industrials
SIXI
Industrials
SIXI
+1.82%
1,750.30
+31.25
+1.82%
—1,719.051,729.911,766.941,729.91——
SIXM
Financials
SIXM
Financials
SIXM
+0.75%
646.61
+4.84
+0.75%
—641.77643.39653.21643.39——
SIXR
Staples
SIXR
Staples
SIXR
+1.26%
833.78
+10.40
+1.26%
—823.38822.99834.38820.61——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1.54%
218.49
+3.31
+1.54%
—215.18215.18218.76215.18——
SIXT
Technology
SIXT
Technology
SIXT
+1.50%
3,109.02
+45.83
+1.50%
—3,063.193,096.933,118.043,093.29——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.42%
935.18
-3.92
-0.42%
—939.10937.35937.41924.95——
SIXV
Health care
SIXV
Health care
SIXV
+1.45%
1,503.60
+21.56
+1.45%
—1,482.041,485.591,506.801,485.59——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+2.36%
2,435.30
+56.09
+2.36%
—2,379.212,409.512,463.802,409.51——
Ironwood Pharmaceuticals, Inc.
$4.43
+2.31%
(+0.100) 1D
$4.44
+0.32% (+0.014)
After hours
Closed: Apr 17, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IRWD...
Open
$4.45
High
$4.50
Low
$4.37
Mkt. cap
722.35M
Avg. vol.
2.65M
Volume
1.96M
P/E ratio
30.06
52-wk high
$5.78
52-wk low
$0.53
EPS
$0.15
Beta
0.17
Shares outstanding
163.06M
No. of employees
100
News stories
From sources across the web
Profile
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea. By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide. Wikipedia
About Ironwood Pharmaceuticals, Inc.
CEO-
Employees100
Founded1998
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websiteironwoodpharma.com
Last report
Feb 25, 2026
Fiscal Period
Q4 2025
Normalized EPS / Estimate
-0.01/ (0.01 est.)USD
-200.00%miss
Revenue / Estimate
47.71M/ (50.93M est.)USD
-6.33%miss
Fiscal Q4 2025 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
41.14M
85.24M
122.06M
47.71M
Cost of goods sold
27.43M
23.37M
22.47M
21.86M
Cost of revenue
27.43M
23.37M
22.47M
21.86M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
24.26M
16.80M
21.91M
19.29M
Operating expense
24.26M
16.80M
21.91M
19.29M
Total operating expenses
51.69M
40.17M
44.38M
41.16M
Operating income
-10.55M
45.07M
77.68M
6.55M
Other non operating income
37.00K
39.00K
40.00K
77.00K
EBT including unusual items
-36.27M
37.82M
68.02M
455.00K
EBT excluding unusual items
-17.71M
37.57M
70.22M
203.00K
Income tax expense
1.11M
14.22M
27.94M
2.73M
Effective tax rate
-3.07%
37.60%
41.08%
600.22%
Other operating expenses
-
-
-
-
Net income
-37.39M
23.60M
40.08M
-2.28M
Net profit margin
-90.87%
27.69%
32.84%
-4.77%
Earnings per share
-0.14
0.14
0.24
-0.01
Interest and investment income
869.00K
818.00K
930.00K
1.46M
Interest expense
-8.07M
-8.36M
-8.43M
-7.89M
Net interest expenses
-7.20M
-7.54M
-7.50M
-6.43M
Depreciation and amortization charges
-
-
-
-
EBITDA
-10.07M
45.54M
78.16M
7.01M
Gain or loss from assets sale
-
85.00K
7.00K
-3.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer